Actavis Laboratories cannot market a generic version of Horizon Pharma’s knee pain treatment, an appeals court has ruled.
Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.
African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority.
California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
The English High Court has sided with pharmaceutical company Vectura and Novartis-owned Sandoz in a passing off lawsuit brought by rival GSK.
The US Court of Appeals for the Federal Circuit last week reversed a Patent Trial and Appeal Board decision, which found that claims in an OSI Pharmaceuticals patent for cancer treatment were obvious.
A US subsidiary of Chinese genome sequencing company BGI has filed a patent infringement counterclaim against Illumina.
Novartis has teamed with Microsoft to launch a new artificial intelligence innovation lab, which it says has the potential to “transform” and “reimagine” medicine.
The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.
Bringing a drug to market is costing companies under $2 billion for the first time in five years, according to a report from IP service provider Clarivate Analytics.